---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-035939"
form_type: "8-K"
ticker: null
cik: "0001693011"
company_name: "Inozyme Pharma, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:45:05.655698+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inozyme reports FY2024 net loss of $102M; cuts 25% workforce to focus on ENPP1 Deficiency

## Summary
- FY2024 net loss $102.0M ($1.62 per share) vs $71.2M ($1.37 per share) in 2023.
- Cash, equivalents & ST investments $113.1M; expects runway into Q1 2026 after prioritization.
- Workforce reduction of ~25%; $1.8M expected charges, substantially complete by Q3 2025.
- Completed enrollment in ENERGY 3 trial (N=27) for INZ-701; topline data expected Q1 2026.
- ABCC6 Deficiency and calciphylaxis trials postponed; only ongoing treatment for existing patients continues.

## SEC filing metadata
- accession: 0000950170-25-035939
- form_type: 8-K
- cik: 0001693011
- company_name: Inozyme Pharma, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1693011/000095017025035939/0000950170-25-035939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1693011/000095017025035939/inzy-20250307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-035939
- JSON: https://secwatch.observer/filing/0000950170-25-035939.json
- Plain text: https://secwatch.observer/filing/0000950170-25-035939.txt

## Key facts
- Restructurings & Charges
  Inozyme Pharma, Inc. announced a restructuring with charges of approximately $1.8 million affecting all areas of the Company (approximately 25%).
  - Type: restructuring
  - Charge: approximately $1.8 million
  - Affected area: all areas of the Company
  - Headcount: approximately 25%
  source text: On March 7, 2025, the Company's Board of Directors approved a reduction of the Company’s workforce by approximately 25% across all areas of the Company, as part of the Company’s decision to prioritize activities to support the planned Biologics License Application filing for INZ-701 for the Company’s lead indication, ENPP1 Deficiency. The Company expects to incur approximately $1.8 million in connection with the workforce reduction, which primarily represents one-time employee termination benefits directly associated with the workforce reduction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1693011/000095017025035939/0000950170-25-035939-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.